Jonathan David Schwartz - 08 Sep 2025 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)

Role
Chief Medical & Gene Therapy Officer
Signature
/s/ Martin Wilson, as attorney-in-fact for Jonathan David Schwartz
Issuer symbol
RCKT
Transactions as of
08 Sep 2025
Transactions value $
$0
Form type
4
Filing time
09 Sep 2025, 16:15:04
Previous filing
20 Aug 2025
Next filing
20 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Schwartz Jonathan David Chief Medical & Gene Therapy Officer C/O ROCKET PHARMACEUTICALS, INC., 9 CEDARBROOK DRIVE, CRANBURY /s/ Martin Wilson, as attorney-in-fact for Jonathan David Schwartz 09 Sep 2025 0001726398

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RCKT Common Stock Award $0 +80K +36.1% $0.00 302K 08 Sep 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.
F2 Represent RSUs that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on September 8, 2026, with the remaining shares vesting in equal quarterly installments over the following two years.

Remarks:

Chief Medical & Gene Therapy Officer